Company intelligence / Profile preview

Imaxio

Paris, Île-de-France, Franceinsights.citeline.com ↗

Ownership: Private
Development stage: Commercial

Overview

Imaxio has developed a marketed vaccine against human leptospirosis in France and leverages its proprietary antigen re-engineering technology to develop new vaccines and companion diagnostics. The company’s R&D led to the creation of Osivax as a spin-off focused on further developing their oligoDOM® antigen engineering technology. The company also applies high-throughput genomics for oncology/immunology diagnostics

Therapeutic areas: Infectious Diseases
Modalities: Recombinant protein vaccinesAntigen re-engineering platforms
Industry: Biotech

Drug pipeline

1 asset

Spirolept

Unknown

Partnerships

Not explicitly listed in search results; likely includes collaborations with academic institutions and possibly pharma partners due to diagnostic/vaccine focus.

Beyond the preview

Go deeper on Imaxio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imaxio.

Explore the full profile